Abstract
Background
Psoriasis is a chronic, systemic, inflammatory condition for which a variety of treatment modalities exist. Combinations of therapies are used often in clinical practice to enhance efficacy and reduce drug toxicities.
Purpose
The purpose of this review is to assess the literature on the efficacy and safety of combination therapy in the treatment of psoriasis.
Methods
MEDLINE was reviewed to identify English-language publications from 1966 to 2011 examining combination therapy in psoriasis. Fifty-three articles met inclusion criteria and were included in this review. Randomized controlled trials addressing various combinations of treatment modalities for psoriasis were included. Data from these clinical studies were summarized and the outcomes were discussed.
Results
Large-scale, randomized controlled trials investigating the use of various combination therapies in psoriasis are limited. The strongest data support the use of combinations of vitamin D derivatives and corticosteroids as topical combinations and, to a lesser extent, the combination of other topical agents. Phototherapy and topical vitamin D derivatives as well as phototherapy in combination with oral retinoids are well supported in the literature. Combinations of systemic medications, though often used clinically, have little data to support their efficacy or safety.
Limitations
Our data were limited by the small number of clinical trials examining the multiple available combinations that are used in clinical practice.
Conclusions
The use of combination treatments falls within the standard of care for psoriasis, even if these combinations have not been extensively studied in clinical trials.
Similar content being viewed by others
References
Zachariae C, Mork NJ, Reunala T, et al. The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy. Acta Derm Venereol. 2008;88(5):495–501.
Lebwohl MG, Breneman DL, Goffe BS, et al. Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis. J Am Acad Dermatol. 1998;39(4 Pt 1):590–6.
Gisondi P, Del GM, Cotena C, et al. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial. Br J Dermatol. 2008;158(6):1345–9.
Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(5):336–41.
Fenton C, Plosker GL. Calcipotriol/betamethasone dipropionate: a review of its use in the treatment of psoriasis vulgaris. Am J Clin Dermatol. 2004;5(6):463–78.
Afifi T, De GG, Huang C, Zhou Y. Topical therapies for psoriasis: evidence-based review. Can Fam Physician. 2005;51:519–25.
Bruner CR, Feldman SR, Ventrapragada M, et al. A systematic review of adverse effects associated with topical treatments for psoriasis. Dermatol Online J. 2003;9(1):2.
Ortonne JP, Kaufmann R, Lecha M, et al. Efficacy of treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: a randomised, double-blind trial. Dermatology. 2004;209(4):308–13.
Papp KA, Guenther L, Boyden B, et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol. 2003;48(1):48–54.
Hudson CP, Kempers S, Menter A, et al. An open-label, multicenter study of the efficacy and safety of a weekday/weekend treatment regimen with calcitriol ointment 3 microg/g and clobetasol propionate spray 0.05% in the management of plaque psoriasis. Cutis. 2011;88(4):201–7.
Menter A, Sofen H, Smith S, et al. An open-label, multicenter study of the efficacy and safety of an AM/PM treatment regimen with clobetasol propionate spray 0.05% and calcitriol ointment 3 microg/g in the management of plaque psoriasis. Cutis. 2011;88(1):46–51.
Austad J, Bjerke JR, Gjertsen BT, et al. Clobetasol propionate followed by calcipotriol is superior to calcipotriol alone in topical treatment of psoriasis. J Eur Acad Dermatol Venereol. 1998;11(1):19–24.
Brodell RT, Bruce S, Hudson CP, et al. A multi-center, open-label study to evaluate the safety and efficacy of a sequential treatment regimen of clobetasol propionate 0.05% spray followed by calcitriol 3 mg/g ointment in the management of plaque psoriasis. J Drugs Dermatol. 2011;10(2):158–64.
Ruzicka T, Lorenz B. Comparison of calcipotriol monotherapy and a combination of calcipotriol and betamethasone valerate after 2 weeks’ treatment with calcipotriol in the topical therapy of psoriasis vulgaris: a multicentre, double-blind, randomized study. Br J Dermatol. 1998;138(2):254–8.
Salmhofer W, Maier H, Soyer HP, et al. Double-blind, placebo-controlled, randomized, right-left study comparing calcipotriol monotherapy with a combined treatment of calcipotriol and diflucortolone valerate in chronic plaque psoriasis. Acta Derm Venereol Suppl (Stockh). 2000;211:5–8.
Katoh N, Kishimoto S. Combination of calcipotriol and clobetasol propionate as a premixed ointment for the treatment of psoriasis. Eur J Dermatol. 2003;13(4):382–4.
Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60(4):643–59.
Koo J, Cuffie CA, Tanner DJ, et al. Mometasone furoate 0.1%-salicylic acid 5% ointment versus mometasone furoate 0.1% ointment in the treatment of moderate-to-severe psoriasis: a multicenter study. Clin Ther. 1998;20(2):283–91.
Tiplica GS, Salavastru CM. Mometasone furoate 0.1% and salicylic acid 5% vs. mometasone furoate 0.1% as sequential local therapy in psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2009;23(8):905–12.
Lebwohl M. Clinical efficacy and safety of tazarotene: optimizing clinical results. Cutis. 1998;61(2 Suppl):27–9.
Guenther LC, Poulin YP, Pariser DM. A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis. Clin Ther. 2000;22(10):1225–38.
Green L, Sadoff W. A clinical evaluation of tazarotene 0.1% gel, with and without a high- or mid-high-potency corticosteroid, in patients with stable plaque psoriasis. J Cutan Med Surg. 2002;6(2):95–102.
Menter A, Abramovits W, Colon LE, et al. Comparing clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 0.064% ointment for the treatment of moderate to severe plaque psoriasis. J Drugs Dermatol. 2009;8(1):52–7.
Monastirli A, Georgiou S, Pasmatzi E, et al. Calcipotriol plus short-contact dithranol: a novel topical combination therapy for chronic plaque psoriasis. Skin Pharmacol Appl Skin Physiol. 2002;15(4):246–51.
Levine D, Even-Chen Z, Lipets I, et al. Pilot, multicenter, double-blind, randomized placebo-controlled bilateral comparative study of a combination of calcipotriene and nicotinamide for the treatment of psoriasis. J Am Acad Dermatol. 2010;63(5):775–81.
Rim JH, Park JY, Choe YB, et al. The efficacy of calcipotriol + acitretin combination therapy for psoriasis: comparison with acitretin monotherapy. Am J Clin Dermatol. 2003;4(7):507–10.
Van De Kerkhof PC, Cambazard F, Hutchinson PE, et al. The effect of addition of calcipotriol ointment (50 micrograms/g) to acitretin therapy in psoriasis. Br J Dermatol. 1998;138(1):84–9.
Gollnick HP. Oral retinoids: efficacy and toxicity in psoriasis. Br J Dermatol. 1996;135(Suppl. 49):6–17.
van der Rhee HJ, Tijssen JG, Herrmann WA, et al. Combined treatment of psoriasis with a new aromatic retinoid (Tigason) in low dosage orally and triamcinolone acetonide cream topically: a double-blind trial. Br J Dermatol. 1980;102(2):203–12.
Grossman RM, Thivolet J, Claudy A, et al. A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: results of a multicenter placebo-controlled study. J Am Acad Dermatol. 1994;31(1):68–74.
Feliciani C, Zampetti A, Forleo P, et al. Nail psoriasis: combined therapy with systemic cyclosporin and topical calcipotriol. J Cutan Med Surg. 2004;8(2):122–5.
Warren RB, Chalmers RJ, Griffiths CE, et al. Methotrexate for psoriasis in the era of biological therapy. Clin Exp Dermatol. 2008;33(5):551–4.
de Jong EM, Mork NJ, Seijger MM, et al. The combination of calcipotriol and methotrexate compared with methotrexate and vehicle in psoriasis: results of a multicentre placebo-controlled randomized trial. Br J Dermatol. 2003;148(2):318–25.
Gupta R, Gupta S. Methotrexate-betamethasone weekly oral pulse in psoriasis. J Dermatolog Treat. 2007;18(5):291–4.
Thaci D, Ortonne JP, Chimenti S, et al. A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study. Br J Dermatol. 2010;163(2):402–11.
Bagel J. LCD plus NB-UVB reduces time to improvement of psoriasis vs. NB-UVB alone. J Drugs Dermatol. 2009;8(4):351–7.
Roussaki-Schulze AV, Kouskoukis C, Klimi E, et al. Calcipotriol monotherapy versus calcipotriol plus UVA1 versus calcipotriol plus narrow-band UVB in the treatment of psoriasis. Drugs Exp Clin Res. 2005;31(5–6):169–74.
Dover JS, McEvoy MT, Rosen CF, et al. Are topical corticosteroids useful in phototherapy for psoriasis? J Am Acad Dermatol. 1989;20(5 Pt 1):748–54.
Torras H, Aliaga A, Lopez-Estebaranz JL, et al. A combination therapy of calcipotriol cream and PUVA reduces the UVA dose and improves the response of psoriasis vulgaris. J Dermatolog Treat. 2004;15(2):98–103.
Ring J, Kowalzick L, Christophers E, et al. Calcitriol 3 microg g-1 ointment in combination with ultraviolet B phototherapy for the treatment of plaque psoriasis: results of a comparative study. Br J Dermatol. 2001;144(3):495–9.
Woo WK, McKenna KE. Combination TL01 ultraviolet B phototherapy and topical calcipotriol for psoriasis: a prospective randomized placebo-controlled clinical trial. Br J Dermatol. 2003;149(1):146–50.
Messer G, Degitz K, Plewig G, et al. Pretreatment of psoriasis with the vitamin D3 derivative tacalcitol increases the responsiveness to 311-nm ultraviolet B: results of a controlled, right/left study. Br J Dermatol. 2001;144(3):628–9.
Ramsay CA, Schwartz BE, Lowson D, et al. Calcipotriol cream combined with twice weekly broad-band UVB phototherapy: a safe, effective and UVB-sparing antipsoriatric combination treatment. The Canadian Calcipotriol and UVB Study Group. Dermatology. 2000;200(1):17–24.
Morison WL, Parrish JA, Fitzpatrick TB. Controlled study of PUVA and adjunctive topical therapy in the management of psoriasis. Br J Dermatol. 1978;98(2):125–32.
Menkes A, Stern RS, Arndt KA. Psoriasis treatment with suberythemogenic ultraviolet B radiation and a coal tar extract. J Am Acad Dermatol. 1985;12(1 Pt 1):21–5.
Mahajan R, Kaur I, Kanwar AJ. Methotrexate/narrowband UVB phototherapy combination vs. narrowband UVB phototherapy in the treatment of chronic plaque-type psoriasis: a randomized single-blinded placebo-controlled study. J Eur Acad Dermatol Venereol. 2010;24(5):595–600.
Lowe NJ, Prystowsky JH, Bourget T, et al. Acitretin plus UVB therapy for psoriasis: comparisons with placebo plus UVB and acitretin alone. J Am Acad Dermatol. 1991;24(4):591–4.
Lauharanta J, Juvakoski T, Lassus A. A clinical evaluation of the effects of an aromatic retinoid (Tigason), combination of retinoid and PUVA, and PUVA alone in severe psoriasis. Br J Dermatol. 1981;104(3):325–32.
Green C, Lakshmipathi T, Johnson BE, et al. A comparison of the efficacy and relapse rates of narrowband UVB (TL-01) monotherapy vs. etretinate (re-TL-01) vs. etretinate-PUVA (re-PUVA) in the treatment of psoriasis patients. Br J Dermatol. 1992;127(1):5–9.
Lebwohl M, Christophers E, Langley R, et al. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol. 2003;139(6):719–27.
Jacobe H, Winterfield L, Kim F, et al. The role of narrowband UV-B plus alefacept combination therapy in the treatment of psoriasis. Arch Dermatol. 2008;144(8):1067–8.
Mease PJ, Reich K. Alefacept with methotrexate for treatment of psoriatic arthritis: open-label extension of a randomized, double-blind, placebo-controlled study. J Am Acad Dermatol. 2009;60(3):402–11.
Reitamo S, Spuls P, Sassolas B, et al. Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial. Br J Dermatol. 2001;145(3):438–45.
Mittal R, Malhotra S, Pandhi P, et al. Efficacy and safety of combination acitretin and pioglitazone therapy in patients with moderate to severe chronic plaque-type psoriasis: a randomized, double-blind, placebo-controlled clinical trial. Arch Dermatol. 2009;145(4):387–93.
Alpsoy E, Ozcan E, Cetin L, et al. Is the efficacy of topical corticosteroid therapy for psoriasis vulgaris enhanced by concurrent moclobemide therapy? A double-blind, placebo-controlled study. J Am Acad Dermatol. 1998;38(2 Pt 1):197–200.
Kerscher M, Volkenandt M, Plewig G, et al. Combination phototherapy of psoriasis with calcipotriol and narrow-band UVB. Lancet. 1993;342(8876):923.
Acknowledgments
No sources of funding were received to prepare this article. Dr. Feldman has received research, speaking and/or consulting support from Galderma Laboratories L.P., GSK/Stiefel, Leo Pharma, Abbott, Amgen, Astellas, Janssen, Taro, National Biological Corporation, National Psoriasis Foundation, and Novartis; he is the founder and majority owner of http://www.DrScore.com, and the founder and part owner of Causa Research, a company dedicated to enhancing patients’ adherence to treatment. The other authors have no conflicts of interest that are directly relevant to the content of this article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gustafson, C.J., Watkins, C., Hix, E. et al. Combination Therapy in Psoriasis. Am J Clin Dermatol 14, 9–25 (2013). https://doi.org/10.1007/s40257-012-0003-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40257-012-0003-7